Advances in sequencing technologies and bioinformatics, coupled with the identification of the sequence of the human genome, have enabled more than a dozen tumor types to be evaluated for mutations over their entire exomes \[Meyerson et al., [@b11]; Stratton, [@b18]\]. These studies have demonstrated that the landscape of each particular tumor type is defined by a small number of genes mutated at a high frequency, called "gene mountains" and a larger number of gene "hills" that are present in a smaller proportion of cases \[Wood et al., [@b25]\].

Members of our group recently used next generation sequencing to evaluate the exomes of ovarian clear cell carcinomas (OCCCs) and identified truncating mutations in *ARID1A* (MIM\# 603024) in 57% of these tumors \[Jones et al., [@b6]\]. Independently, Wiegand et al. \[[@b23]\] discovered a high prevalence of *ARID1A* mutations in both OCCC (45%) and endometriod carcinoma of the ovary (30%). Combining both studies, two mutations were identified in the same tumor in 30% of the mutated cases, which, taken together with the inactivating nature of the mutations and their remarkable frequency, provided unequivocal evidence that *ARID1A* is a tumor suppressor gene in these two tumor types. In addition, loss of *ARID1A* expression was observed in approximately 20% of uterine carcinomas \[Wiegand et al., [@b22]\]. In previous studies, chromosomal translocations involving *ARID1A* were identified in a breast and a lung cancer, though the interpretation of these alterations was challenging \[Huang et al., [@b5]\].

The protein encoded by *ARID1A* is a key component of the highly conserved SWI--SNF (switch/sucrose non-fermentable) chromatin remodeling complex that uses adenosine triphosphate (ATP)-dependent helicase activities to allow access of transcriptional activators and repressors to DNA \[Wang et al., [@b20]; Wilson and Roberts, [@b24]\]. The protein therefore appears to be involved in regulating processes including DNA repair, differentiation, and development \[[@b21]\]. Functional studies by Nagl et al. \[[@b13]\] have demonstrated that the SWI--SNF complex suppresses proliferation. The *ARID1A-*encoded protein, BAF250a, is one of two mutually exclusive ARID1 subunits. BAF250a has a DNA-binding domain that specifically binds to AT-rich DNA sequences and is thought to confer specificity to the complex \[Wu et al., [@b26]\].

Passenger mutations are best defined as those that do not confer a selective growth advantage to the cells in which they occur, while driver mutations are those which do confer a growth advantage. It is often difficult to distinguish driver mutations from passenger mutations when the mutations occur at low frequency. One of the best examples of this challenge is provided by *IDH1* mutations. A single mutation of *IDH1*, R132H, was discovered in a whole exomic screen of 11 colorectal cancers (CRCs) \[Sjöblom et al., [@b17]\]. This mutation was not identified in more than 200 additional CRC samples and was presumed to be a passenger mutation. However, frequent *IDH1* mutations at the identical residue were found when brain tumors, such as lower grade astrocytomas and oligodendrogliomas were evaluated \[Parsons et al., [@b14]; Yan et al., [@b27]\]. Thus, the *IDH1* mutation in that original CRC in retrospect was undoubtedly a driver.

This example illustrates that once a genetic alteration is identified as a driver in one tumor type, infrequent mutations of the same type in the same gene in other tumors can be more reliably interpreted. Given that, it is now known that *ARID1A* is a bona fide tumor suppressor gene in OCCC, we applied this principle to the evaluation of *ARID1A* mutations in other tumor types. As described below, we studied more than 700 different neoplasms of seven different types using Sanger sequencing to determine the contribution of *ARID1A* alterations to tumorigenesis in general.

Somatic mutations were identified in 43 of the 759 neoplasms studied (6%) ([Table 1](#tbl1){ref-type="table"}). Eight neoplasms contained two or three (one case) different mutations, presumably on different alleles, so the total number of mutations was 52. A relatively high frequency of mutations was observed in neoplasms of the colon (10%; 12/119), stomach (10%; 10/100), and pancreas (8%; 10/119). Though only a small number of prostate tumors was available for study, we identified two carcinomas with mutations among the 23 studied. Mutations were observed in three of 125 (2%) medulloblastomas, in four of 114 (4%) breast cancers, and in two of 36 (6%) lung carcinomas ([Table 1](#tbl1){ref-type="table"}; [Fig. 1](#fig01){ref-type="fig"}). No mutations were observed among 34 glioblastomas or 89 leukemias tested.

###### 

Mutations in the Chromatin Remodeling Gene, *ARID1A*

  Sample                                    Tumor type        Nucleotide (genomic)[b](#tf1-2){ref-type="table-fn"}   Nucleotide (cDNA)[c](#tf1-3){ref-type="table-fn"}   Amino acid (protein)   Mutation type   MSI status
  ----------------------------------------- ----------------- ------------------------------------------------------ --------------------------------------------------- ---------------------- --------------- ------------
  399                                       Breast            g.chr1:26928914delC                                    c.1323delC                                          Fs                     Indel           MSS
  3814                                      Breast            g.chr1:26979235G\>A                                    c.6259G\>A                                          p.G2087R               Missense        MSS
  5887                                      Breast            g.chr1:26978695A\>T                                    c.5719A\>T                                          p.I1907F               Missense        MSS
  C-122                                     Breast            g.chr1:26965396C\>T                                    c.2830C\>T                                          p.Q944X                Nonsense        MSS
  Co001                                     Colon             g.chr1:26896495delG                                    c.1014delG                                          Fs                     Indel           MSI-high
  Co001                                     Colon             g.chr1:26973994delC                                    c.4689delC                                          Fs                     Indel           MSI-high
  Co014                                     Colon             g.chr1:26970279delA                                    c.3281delA                                          Fs                     Indel           MSI-high
  Co024                                     Colon             g.chr1:26970342delC                                    c.3344delC                                          Fs                     Indel           MSI-high
  Co024                                     Colon             g.chr1:26978524delG                                    c.5548delG                                          Fs                     Indel           MSI-high
  Co038                                     Colon             g.chr1:26973659delC                                    c.4354delC                                          Fs                     Indel           MSI-high
  Co038                                     Colon             g.chr1:26978524delG                                    c.5548delG                                          Fs                     Indel           MSI-high
  Co083                                     Colon             g.chr1:26978524delG                                    c.5548delG                                          Fs                     Indel           MSI-high
  Co097                                     Colon             g.chr1:26978524dupG                                    c.5548dupG                                          Fs                     Indel           MSI-high
  Hx132                                     Colon             g.chr1:26931798delC                                    c.1848delC                                          Fs                     Indel           ND
  Hx132                                     Colon             g.chr1:26965600_26965602delAAC                         c.2944_2946delAAC                                   In-frame del           Indel           ND
  Hx164                                     Colon             g.chr1:26930536C\>T                                    c.1657C\>T                                          p.Q553X                Nonsense        MSS
  Hx245                                     Colon             g.chr1:26979204C\>A                                    c.6228C\>A                                          p.Y2076X               Nonsense        MSS
  Hx290                                     Colon             g.chr1:26978814_26978820dupACAGAGC (hom)               c.5838_5844dupACAGAGC                               Fs                     Indel           MSS
  Hx308                                     Colon             g.chr1:26978810_26978811insAGCACAG                     c.5834_5835insAGCACAG                               Fs                     Indel           ND
  Hx326                                     Colon             g.chr1:26962098_26962099dupTA                          c.2467_2468dupTA                                    Fs                     Indel           MSS
  G07                                       Gastric           g.chr1:26896360dupC                                    c.879dupC                                           Fs                     Indel           MSI-high
  G08                                       Gastric           g.chr1:26896308delG                                    c.827delG                                           Fs                     Indel           MSI-high
  G13                                       Gastric           g.chr1:26974048_26974049delCA                          c.4743_4744delCA                                    Fs                     Indel           MSI-high
  G13                                       Gastric           g.chr1:26978524delG                                    c.5548delG                                          Fs                     Indel           MSI-high
  G13                                       Gastric           g.chr1:26974277C\>T                                    c.4972C\>T                                          p.R1658W               Missense        MSI-high
  G18                                       Gastric           g.chr1:26978335G\>T                                    c.5359G\>T                                          p.E1787X               Nonsense        MSS
  G21                                       Gastric           g.chr1:26978524delG                                    c.5548delG                                          Fs                     Indel           MSI-high
  G24                                       Gastric           g.chr1:26973829T\>A                                    c.4524T\>A                                          p.Y1508X               Nonsense        MSI-high
  G61                                       Gastric           g.chr1:26978524delG                                    c.5548delG                                          Fs                     Indel           ND
  G61                                       Gastric           g.chr1:26979396delC                                    c.6420delC                                          Fs                     Indel           ND
  G84                                       Gastric           g.chr1:26961335dupG                                    c.2357dupG                                          Fs                     Indel           MSS
  G144                                      Gastric           g.chr1:26896335delG                                    c.854delG                                           Fs                     Indel           MSS
  G280                                      Gastric           g.chr1:26896450_26896456delGGGCGCC                     c.969_975delGGGCGCC                                 Fs                     Indel           MSS
  L11C                                      Lung              g.chr1:26965400delG                                    c.2834delG                                          Fs                     Indel           ND
  L17C                                      Lung              g.chr1:26979379_26979384delATTCTG                      c.6403_6408delATTCTG                                In-frame del           Indel           MSS
  MB118PT[a](#tf1-1){ref-type="table-fn"}   Medulloblastoma   g.chr1:26896496delG                                    c.1015delG                                          Fs                     Indel           MSS
  MB155PT                                   Medulloblastoma   g.chr1:26974198_26974199InsC                           c.4893_4894InsC                                     Fs                     Indel           MSS
  MB156PT                                   Medulloblastoma   g.chr1:26974673delG                                    c.5012delG                                          Fs                     Indel           MSS
  Pa07C[a](#tf1-1){ref-type="table-fn"}     Pancreas          g.chr1:26972534C\>T                                    c.3826C\>T                                          p.R1276X               Nonsense        MSS
  Pa37X                                     Pancreas          g.chr1:26978923_26978924delTG                          c.5947_5948delTG                                    Fs                     Indel           MSS
  Pa102C[a](#tf1-1){ref-type="table-fn"}    Pancreas          g.chr1:26965645G\>A                                    IVS10+1G\>A                                         Splice site            Splice site     MSS
  Pa144X                                    Pancreas          g.chr1:26959958_26959959insT                           c.1945_1946insT                                     Fs                     Indel           MSS
  Pa158X                                    Pancreas          g.chr1:26961274dupC                                    c.2296dupC                                          Fs                     Indel           MSS
  Pa166X                                    Pancreas          g.chr1:26978941C\>T                                    c.5965C\>T                                          p.R1989X               Nonsense        MSS
  Pa194X                                    Pancreas          g.chr1:26978941C\>T                                    c.5965C\>T                                          p.R1989X               Nonsense        MSS
  Pa194X                                    Pancreas          g.chr1:26979263C\>G                                    c.6287C\>G                                          p.S2096X               Nonsense        MSS
  Pa197X                                    Pancreas          g.chr1:26930464C\>T                                    c.1585C\>T                                          p.Q529X                Nonsense        MSS
  Pa198X                                    Pancreas          g.chr1:26978524dupG                                    c.5548dupG                                          Fs                     Indel           MSS
  Pa216X                                    Pancreas          g.chr1:26961380delG                                    c.2402delG                                          Fs                     Indel           MSS
  SW32                                      Prostate          g.chr1:26972768delC                                    c.3977delC                                          Fs                     Indel           ND
  SW32                                      Prostate          g.chr1:26978524dupG                                    c.5548dupG                                          Fs                     Indel           ND
  Pr04PT                                    Prostate          g.chr1:26972790_26972792het_delGCA                     c.3999_4101delGCA                                   In-frame del           Indel           MSI-high

Mutation previously reported.

Genomic co-ordinates refer to hg18.

Reference sequence CCDS285.1.

MSI, microsatellite instability; MSS, microsatellite stable; ND, not determined.

![A: Examples of truncating mutations in *ARID1A* in gastric, colon, breast, and pancreatic cancers. Arrows indicate the position of the mutation. Note that in the breast primary tumor (399), there were contaminating nonneoplastic cells that reduced the relative peak heights of the mutant alleles. B: Distribution and types of mutations identified in *ARID1A* to date. Exons are indicated in blue with the ARID (AT-rich interactive domain), DNA-binding domain shown in green, the HIC (hypermethylated in cancer) domain in purple, and the LXXLL (leucine rich) motifs in pink. Black arrows indicate the position of insertion or deletion mutations, red arrows indicate nonsense mutations, blue arrows indicate missense variants, and gray arrows indicate splice site alterations. Mutations listed above the figure represent those reported in this study; those below were identified in Jones et al. \[[@b6]\] and Wiegand et al. \[[@b23]\] in ovarian cancers; Gui et al. \[[@b4]\] in bladder cancer; Varela et al. in renal cancer, and Birnbaum et al. in pancreatic cancer.](humu0033-0100-f1){#fig01}

As expected for inactivating mutations of a tumor suppressor gene, the mutations were distributed throughout the gene and included nonsense variants, out-of-frame and in-frame small insertions and deletions, as well as a small number (three) of missense changes. Mutations were most commonly observed in a seven-base G tract around position g.chr1:26978524 (genomic coordinates refer to hg18) (c.5548), where there were six single base pair deletions and three duplications among gastric, colon, prostate, and pancreas carcinomas. This G tract is the longest mononucleotide repeat in the coding region and the probability of slippage at mononucleotide repeats clearly increases with run length \[Eshleman et al., [@b3]; Markowitz et al., [@b9]\]. Thirty-eight of the 43 samples with somatic mutations were available for microsatellite instability (MSI) testing. Twelve tumors (six colon, five gastric, and one prostate) were shown to be MSI high, and all carried mutations at mononucleotide tracts in the *ARID1A* gene ([Table 1](#tbl1){ref-type="table"}). It is therefore possible that *ARID1A*, such as *TGFβRII* or *BAX*, is associated with MSI and that the homopolymeric repeat frameshifts may result from defects in mismatch repair \[Markowitz et al., [@b9]; Rampino et al., [@b16]\]. Though the interpretation of mutations in mismatch repair-deficient tumors is challenging \[Kern, [@b8]\], the fact that approximately 40% of the CRCs with *ARID1A* mutations did not have MSI leaves little doubt that *ARID1A* plays a role in this tumor type.

The identification of mutations in *ARID1A* in several different types of cancer indicates that this gene has a wider role in human tumorigenesis than previously appreciated. These findings are supported by the demonstration of loss of the ARID1A protein, BAF250a, by immunohistochemistry in 14% of gastric and anaplastic thyroid carcinomas \[Wiegand et al., [@b22]\] and by the identification of *ARID1A* point mutations in 3 of 48 pancreatic cancers by Birnbaum et al. \[[@b1]\]. More recently, ARID1A mutations have also been observed in 13% of bladder carcinomas \[Gui et al., [@b4]\]. In addition, *ARID1A* appears to be frequently mutated in gastrointestinal tumors displaying high levels of MSI. Mutations in other members of the SWI--SNF chromatin remodeling complex have also been reported. For example, truncating mutations in *SMARCA4/BRG1* were identified in three pancreatic cancers, in a medulloblastoma, and in several lung cancers \[Jones et al., [@b7]; Medina et al., [@b10]; Parsons et al., [@b15]\]. More recently, 41% of renal cancers have been shown to have truncating mutations in the SWI--SNF chromatin remodeling complex gene, *PBRM1* \[Varela et al., [@b19]\]. In addition, a pattern of somatic mutation of genes involved more generally in chromatin remodeling is starting to appear. *MLL3* appears to be involved in a small number of colon and pancreatic cancers and medulloblastomas \[Jones et al., [@b7]; Parsons et al., [@b15]; Wood et al., [@b25]\]; *MLL2* is mutated in 14% of medulloblastomas and a large fraction of non-Hodgkin\'s lymphomas \[Morin et al., [@b12]; Parsons et al., [@b15]\] and *JARID1C* is genetically altered in a small proportion of kidney cancers \[Dalgliesh et al., [@b2]\]. These data collectively link genetic alterations to epigenetic changes and pave the way for a better understanding of both.
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